drugset / Trial / NCT01658319
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1
Completed
20 enrolled
Case Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial is studying the side effects and best dose of methoxyamine when given together with fludarabine phosphate in treating patients with relapsed or refractory hematologic malignancies. Drugs used in chemotherapy, such as methoxyamine and fludarabine phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving methoxyamine together with fludarabine phosphate may kill more cancer cells.
Timeline
- Start
- 2011-05
- Primary completion
- 2015-02
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methoxyamine | Small molecule | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |
Indications
Burkitt lymphoma
Hodgkins lymphoma
MALT lymphoma
Waldenstrom macroglobulinemia
adult T-cell leukemia/lymphoma
anaplastic large cell lymphoma
angioimmunoblastic T-cell lymphoma
chronic lymphocytic leukemia/small lymphocytic lymphoma
chronic myeloid leukemia
extranodal nasal NK/T cell lymphoma
grade III lymphomatoid granulomatosis
hepatosplenic T-cell lymphoma
intraocular lymphoma
large-cell immunoblastic lymphoma
lymphoblastic lymphoma
mantle cell lymphoma
mycosis fungoides and variants
nodal marginal zone B-cell lymphoma
peripheral T-cell lymphoma, not otherwise specified
plasma cell myeloma
primary cutaneous B-cell lymphoma
small intestine lymphoma
splenic marginal zone lymphoma
testicular lymphoma